How Is AI Used in Healthcare and Health Innovation?

Artificial Intelligence (AI) is a concept about which we have been aware for some time. It has been a popular topic of speculation in science fiction for centuries, but now we are closer than ever to living the fiction. The breakneck pace of tech innovation globally has seen recent breakthroughs in machine learning, and ‘intelligent’ algorithms have already been made available to consumers.

A tech revolution is at hand, and all sectors will see profound shifts as a result – none more, perhaps, than healthcare. Healthcare innovation is nothing short of vital, and AI could be the solution for many of the UK’s NHS issues. But how, exactly?

Improving Diagnostics

One of the leading areas in which Ai is seeing major healthcare innovation is through diagnostics. The time of healthcare professionals in primary care capacities is often taken up by patient intake and initial diagnostics, which can divert a lot of time and energy from effective treatment and patient engagement. AI systems are being developed to take these initial diagnostics out of doctors’ hands; patient symptoms are recorded and interpreted by the AI system, and the patients are automatically referred to the relevant department.

Diagnostic improvements extend from primary care and GP centres to the heart of specialist hospitals and urgent care systems. Similar systems can be used to find unique and unusual patterns in patient symptoms or readings, allowing for a more nuanced investigation of potential causes. In this way, early disease detection is expected to improve dramatically, alongside outcomes for urgent care patients.

Drug Discovery

Speaking of outcomes, AI systems will have a vital role to play in the development of new treatments – particularly the development and discovery of effective drugs. The drug discovery pipeline is necessarily slow and methodical, so as not to unnecessarily endanger life in the trialling of unknown quantities.

The superior computational and modelling power of purpose-built AI systems will enable the quicker and safer synthesis of new potential compounds – and could vastly speed up initial research timelines. Careful trialling and investigation will still be a necessity – as will the legal counsel of life sciences specialists in the coordination of safe and legal drug discovery – but the existence of such intelligent systems could revolutionise the understanding of the chemistry behind initial drug testing.

Medical Imagery

The aforementioned role of AI in diagnostic improvements is a field in and of itself, but there is a tangentially related field of AI development that could further improve patient outcomes concerning the interpretation of data. Many patients require scans to identify issues, be they sources of bleeding, potential tumour presences, or simply broken bones. However, there are elements of human error in the interpretation of scan results, whether visual or data-based.

In training machine learning algorithms on wide data sets of existing MRI or CAT-scan imagery, AI can be developed for the express purpose of reading and interpreting scan information. This could greatly reduce the levels of human error in patient diagnosis and treatment, to say nothing of the additional nuance with which an AI can interpret scan data.

 

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.